| This sample attributes table includes body site where sample was extracted, analyte type, tumor status, histological type, sequence in which sample was collected, first and second line of tumor treatment, and name of sequencing center. | First line therapy given in each case | phv00218119.v1.p1 |
| This subject phenotype table includes subject's sex, age of onset, prognostic marker ZAP70 and CD38, and the IGHV locus mutation status. | Molecular Prognostic marker in CLL - ZAP 70 | phv00218109.v1.p1 |
| This subject phenotype table includes subject's sex, age of onset, prognostic marker ZAP70 and CD38, and the IGHV locus mutation status. | IGHV locus mutation status | phv00218112.v1.p1 |
| The subject consent data table contains subject IDs and consent information. | Consent group as determined by DAC | phv00218103.v1.p1 |
| This data table contains mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample use. | Sample Use | phv00218106.v1.p1 |
| This data table contains mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample use. | Subject ID | phv00218104.v1.p1 |
| This sample attributes table includes body site where sample was extracted, analyte type, tumor status, histological type, sequence in which sample was collected, first and second line of tumor treatment, and name of sequencing center. | Seondary therapy provided after relapse | phv00218120.v1.p1 |
| This sample attributes table includes body site where sample was extracted, analyte type, tumor status, histological type, sequence in which sample was collected, first and second line of tumor treatment, and name of sequencing center. | Cell or tissue type or subtype of sample | phv00218117.v1.p1 |
| This sample attributes table includes body site where sample was extracted, analyte type, tumor status, histological type, sequence in which sample was collected, first and second line of tumor treatment, and name of sequencing center. | Body site where sample was collected | phv00218114.v1.p1 |
| This subject phenotype table includes subject's sex, age of onset, prognostic marker ZAP70 and CD38, and the IGHV locus mutation status. | Gender of participant | phv00218111.v1.p1 |
| This sample attributes table includes body site where sample was extracted, analyte type, tumor status, histological type, sequence in which sample was collected, first and second line of tumor treatment, and name of sequencing center. | Tumor status | phv00218116.v1.p1 |
| This subject phenotype table includes subject's sex, age of onset, prognostic marker ZAP70 and CD38, and the IGHV locus mutation status. | Molecular Prognostic marker in CLL - CD38 | phv00218110.v1.p1 |
| This sample attributes table includes body site where sample was extracted, analyte type, tumor status, histological type, sequence in which sample was collected, first and second line of tumor treatment, and name of sequencing center. | De-identified Sample ID | phv00218113.v1.p1 |
| This subject phenotype table includes subject's sex, age of onset, prognostic marker ZAP70 and CD38, and the IGHV locus mutation status. | De-identified Subject ID | phv00218107.v1.p1 |
| The subject consent data table contains subject IDs and consent information. | Subject ID | phv00218102.v1.p1 |
| This sample attributes table includes body site where sample was extracted, analyte type, tumor status, histological type, sequence in which sample was collected, first and second line of tumor treatment, and name of sequencing center. | Sample obtained sequentially from Subjects | phv00218118.v1.p1 |
| This sample attributes table includes body site where sample was extracted, analyte type, tumor status, histological type, sequence in which sample was collected, first and second line of tumor treatment, and name of sequencing center. | Analyte Type | phv00218115.v1.p1 |
| This sample attributes table includes body site where sample was extracted, analyte type, tumor status, histological type, sequence in which sample was collected, first and second line of tumor treatment, and name of sequencing center. | Name of the center which conducted sequencing | phv00218121.v1.p1 |
| This subject phenotype table includes subject's sex, age of onset, prognostic marker ZAP70 and CD38, and the IGHV locus mutation status. | Disease onset age | phv00218108.v1.p1 |
| This data table contains mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample use. | Sample ID | phv00218105.v1.p1 |